Ipratropiumbromid Hexal (Ipratropium Bromide Monohydrate)

Ipratropium bromide competitively blocks muscarinic (M3) receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction. By inhibiting this parasympathetic pathway, the drug promotes bronchodilation, decreases airway resistance, and facilitates easier breathing in patients with obstructive lung disease. Its anticholinergic action is localized to the respiratory tract when delivered by inhalation, limiting systemic exposure.

The specific dose and frequency are determined by the prescribing clinician based on the individual’s disease severity, response to therapy, and other clinical factors. Ipratropium bromide is typically administered via a metered‑dose inhaler or nebulizer, and the prescriber will provide detailed instructions on the number of puffs or nebulization time appropriate for each patient.

Safety data for ipratropium bromide in pregnancy are limited, and the product is generally classified as a Category C medication, meaning it should only be used if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as small amounts may be excreted in breast milk. The prescriber will weigh risks and benefits before recommending use.

To place an order, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity of Ipratropiumbromid Hexal. GNH India works with hospitals, pharmacies, and procurement teams worldwide, requesting verification of trade or institutional credentials. After review, the sales team will respond with pricing, availability, shipping details—including any cold‑chain requirements—and necessary import documentation.

Ipratropium bromide belongs to the anticholinergic class, offering a mechanism distinct from β2‑agonists such as albuterol. It provides additive bronchodilation when combined with short‑acting β2‑agonists, and its effects are generally longer lasting than short‑acting agents but shorter than long‑acting muscarinic antagonists (LAMAs) like tiotropium. Choice of therapy depends on disease severity, patient response, and physician preference.

The product should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture, heat, and direct sunlight. Do not freeze the inhalation device or expose it to extreme temperatures, as this may affect the stability of the active ingredient. Always keep the container tightly closed when not in use.

Ipratropiumbromid Hexal is delivered by inhalation, either through a metered‑dose inhaler (MDI) or a nebulizer solution, depending on the formulation supplied. The patient inhales the medication directly into the lungs, allowing rapid onset of bronchodilation. Proper technique, including breath coordination for MDIs or appropriate nebulizer settings, should be taught by a healthcare professional to ensure optimal drug delivery.

Although generally well tolerated, serious adverse events can occur. These include paradoxical bronchospasm, which may worsen breathing difficulty, and severe allergic reactions such as angioedema or anaphylaxis. Cardiovascular effects like tachycardia and urinary retention have also been reported. Patients should seek immediate medical attention if they experience sudden worsening of respiratory symptoms, swelling of the face or throat, or rapid heartbeat.

Ipratropiumbromid Hexal is contraindicated in individuals with a known hypersensitivity to ipratropium bromide or any of the product’s excipients. Caution is advised for patients with narrow‑angle glaucoma, urinary retention, or severe gastrointestinal obstruction, as anticholinergic effects may exacerbate these conditions. The prescribing clinician will assess medical history to determine suitability before initiating therapy.